Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

1.

Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study.

Yu SY, Zuo LJ, Wang F, Chen ZJ, Hu Y, Wang YJ, Wang XM, Zhang W.

BMC Neurol. 2014 May 22;14:113. doi: 10.1186/1471-2377-14-113.

PMID:
24884485
[PubMed - in process]
Free PMC Article
2.

Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM; Parkinson's Progression Markers Initiative.

JAMA Neurol. 2013 Oct;70(10):1277-87.

PMID:
23979011
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease.

Parnetti L, Farotti L, Eusebi P, Chiasserini D, De Carlo C, Giannandrea D, Salvadori N, Lisetti V, Tambasco N, Rossi A, Majbour NK, El-Agnaf O, Calabresi P.

Front Aging Neurosci. 2014 Mar 31;6:53. doi: 10.3389/fnagi.2014.00053. eCollection 2014.

PMID:
24744728
[PubMed]
Free PMC Article
4.

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K.

JAMA. 2009 Jul 22;302(4):385-93. doi: 10.1001/jama.2009.1064.

PMID:
19622817
[PubMed - indexed for MEDLINE]
5.

Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease.

Compta Y, Martí MJ, Ibarretxe-Bilbao N, Junqué C, Valldeoriola F, Muñoz E, Ezquerra M, Ríos J, Tolosa E.

Mov Disord. 2009 Nov 15;24(15):2203-10. doi: 10.1002/mds.22594.

PMID:
19795497
[PubMed - indexed for MEDLINE]
6.

CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease.

Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J.

Acta Neuropathol. 2013 Nov;126(5):683-97. doi: 10.1007/s00401-013-1148-z. Epub 2013 Jun 29.

PMID:
23812319
[PubMed - indexed for MEDLINE]
7.

Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.

Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, Padiglioni C, Mastrocola S, Lisetti V, Calabresi P.

J Alzheimers Dis. 2012;29(1):229-38. doi: 10.3233/JAD-2011-111349.

PMID:
22232006
[PubMed - indexed for MEDLINE]
8.

Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease.

Johansson P, Åberg D, Johansson JO, Mattsson N, Hansson O, Ahrén B, Isgaard J, Åberg ND, Blennow K, Zetterberg H, Wallin A, Svensson J.

Psychoneuroendocrinology. 2013 Sep;38(9):1729-37. doi: 10.1016/j.psyneuen.2013.02.006. Epub 2013 Mar 6.

PMID:
23473966
[PubMed - indexed for MEDLINE]
9.

Analysis of combined CSF biomarkers in AD diagnosis.

De Riva V, Galloni E, Marcon M, Di Dionisio L, Deluca C, Meligrana L, Bolner A, Perini F.

Clin Lab. 2014;60(4):629-34.

PMID:
24779297
[PubMed - indexed for MEDLINE]
10.

Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia.

Compta Y, Ibarretxe-Bilbao N, Pereira JB, Junqué C, Bargalló N, Tolosa E, Valldeoriola F, Muñoz E, Camara A, Buongiorno M, Martí MJ.

Parkinsonism Relat Disord. 2012 Sep;18(8):941-7. doi: 10.1016/j.parkreldis.2012.04.028. Epub 2012 May 15.

PMID:
22595621
[PubMed - indexed for MEDLINE]
11.

Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.

Maccioni RB, Lavados M, Guillón M, Mujica C, Bosch R, Farías G, Fuentes P.

Neurobiol Aging. 2006 Feb;27(2):237-44. Epub 2005 Apr 7.

PMID:
16399209
[PubMed - indexed for MEDLINE]
12.

Cerebrospinal fluid biomarkers and prediction of conversion in patients with mild cognitive impairment: 4-year follow-up in a routine clinical setting.

Lanari A, Parnetti L.

ScientificWorldJournal. 2009 Sep 15;9:961-6. doi: 10.1100/tsw.2009.106.

PMID:
19768352
[PubMed - indexed for MEDLINE]
Free Article
13.

Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.

Rami L, Fortea J, Bosch B, Solé-Padullés C, Lladó A, Iranzo A, Sánchez-Valle R, Molinuevo JL.

J Alzheimers Dis. 2011;23(2):319-26. doi: 10.3233/JAD-2010-101422.

PMID:
21098971
[PubMed - indexed for MEDLINE]
14.

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.

Rolinski M, Fox C, Maidment I, McShane R.

Cochrane Database Syst Rev. 2012 Mar 14;3:CD006504. doi: 10.1002/14651858.CD006504.pub2. Review.

PMID:
22419314
[PubMed - indexed for MEDLINE]
15.

Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.

Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K.

Acta Neurol Scand Suppl. 2003;179:47-51.

PMID:
12603251
[PubMed - indexed for MEDLINE]
16.

Amyloid-β and τ biomarkers in Parkinson's disease-dementia.

Buongiorno M, Compta Y, Martí MJ.

J Neurol Sci. 2011 Nov 15;310(1-2):25-30. doi: 10.1016/j.jns.2011.06.046. Epub 2011 Jul 20. Review.

PMID:
21764078
[PubMed - indexed for MEDLINE]
17.

Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.

Frankfort SV, Tulner LR, van Campen JP, Verbeek MM, Jansen RW, Beijnen JH.

Curr Clin Pharmacol. 2008 May;3(2):123-31. Review.

PMID:
18700307
[PubMed - indexed for MEDLINE]
18.

CSF biomarker changes precede symptom onset of mild cognitive impairment.

Moghekar A, Li S, Lu Y, Li M, Wang MC, Albert M, O'Brien R; BIOCARD Research Team.

Neurology. 2013 Nov 12;81(20):1753-8. doi: 10.1212/01.wnl.0000435558.98447.17. Epub 2013 Oct 16.

PMID:
24132375
[PubMed - indexed for MEDLINE]
19.

Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.

Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Andreasson U, Zetterberg H, Blennow K, Svensson J.

J Alzheimers Dis. 2011;24(3):537-46. doi: 10.3233/JAD-2011-101878.

PMID:
21297262
[PubMed - indexed for MEDLINE]
20.

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.

Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.

Arch Gen Psychiatry. 2012 Jan;69(1):98-106. doi: 10.1001/archgenpsychiatry.2011.155.

PMID:
22213792
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk